Drug safety excellence in PSP selection

Drug safety excellence in PSP selection Selecting a patient support program (PSP) vendor involves careful consideration of many factors, with drug safety excellence being an essential priority. At Innomar Strategies, we recognize the critical role drug safety plays in maintaining compliance, accurate reporting, and ultimately, protecting patients. In this video, Jignashu Shah, Director of Drug Safety, discusses how our team’s expertise in adverse event reporting and regulatory alignment helps support efforts to reduce risk and safeguard patients.

Transcript of 'Drug safety excellence in PSP selection'

Why is drug safety excellence a critical factor in selecting a PSP vendor?

Drug safety excellence is a critical factor in the broader patient support program selection process for several reasons: 

The pharmaceutical industry is fundamentally based on trust, patient safety, and adherence to regulatory standards. 

While operational efficiency and patient outcomes are often prioritized by pharmaceutical manufacturers and procurement managers when selecting a PSP vendor, drug safety excellence is a  non-negotiable element that should not be overlooked. 

The drug safety team plays a crucial role in safety information reporting  within a PSP. 

Deficiencies or gaps in adverse event reporting processes can lead to significant issues, including compliance risks, inaccurate reporting, regulatory scrutiny, and most importantly, potential harm to patients. 

By prioritizing drug safety, pharmaceutical manufacturers can help significantly reduce risk, improve reporting accuracy, and maintain long-term regulatory confidence. 

At Innomar, our team exemplifies operational efficiency and excellence in drug safety within the PSP landscape. 

That’s why pharmaceutical manufacturers can trust our drug safety team’s expertise to uphold regulatory alignment and safety excellence. 

The information provided in this piece does not constitute legal or medical advice. Innomar Strategies Inc. and its parent Cencora, Inc. strongly encourage the audience to review available information related to the topics discussed to rely on their own experience and expertise in making decisions related thereto. Further, the contents of this piece are owned by Innomar Strategies, and reproduction is not permitted without the consent of Innomar Strategies.